Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis

DARU Journal of Pharmaceutical Sciences - 2012
Shekoufeh Nikfar1, Roja Rahimi2, Narjes Hendoiee3, Mohammad Abdollahi2
1Food and Drug Laboratory Research Center, Food and Drug Organisation, Tehran, Iran
2Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
3Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

Tóm tắt

Abstract Selective serotonin reuptake inhibitors (SSRIs) are the most frequently used antidepressants during pregnancy. There are conflicting results about their influence on pregnancy outcomes. The goal of this study was to update our previous meta-analysis about pregnancy outcomes following exposure to SSRIs. For this purpose, all relevant databases were searched from 1990 to March 2012 for studies investigating the pregnancy outcomes following exposure to any therapeutic dosage of any SSRI (fluoxetine, paroxetine, citalopram, escitalopram, sertraline, fluvoxamine) during pregnancy. Types of outcome investigated were spontaneous abortion, major malformations, cardiovascular malformations, and minor malformations. A total of 25 studies met our criteria and were included in the meta-analysis. The odds ratio (OD) values are 1.87 (95% CI: 1.5 to 2.33, P< 0.0001) for spontaneous abortion, 1.272 (95% CI: 1.098 to 1.474, P = 0.0014) for major malformations, 1.192 (95% CI: 0.39 to 3.644, P= 0.7578) for cardiovascular malformations, and 1.36 (95% CI: 0.61 to 3.04, P= 0.4498) for minor malformations. The results demonstrated that SSRIs increase the risk of spontaneous abortion and major malformations during pregnancy while they don’t increase the risk of cardiovascular malformations and minor malformations. Our previous meta-analysis only showed an increase in the risk of spontaneous abortion following the use of SSRIs during pregnancy. This might be due to increase in the number of studies included or addition of two new SSRIs (citalopram and escitalopram). The message to researchers is to try considering SSRIs individually during pregnancy to reduce heterogeneity, although all are aware of inevitable limitations to study on pregnant mothers.

Từ khóa


Tài liệu tham khảo

Nasreen HE, Kabir ZN, Forsell Y, Edhborg M: Prevalence and associated factors of depressive and anxiety symptoms during pregnancy: a population based study in rural Bangladesh. BMC Women’s Health. 2011, 11: 22-10.1186/1472-6874-11-22.

Hartley M, Tomlinson M, Greco E, Comulada WS, Stewart J, le Roux I, Mbewu N, Rotheram-Borus MJ: Depressed mood in pregnancy: prevalence and correlates in two Cape Town peri-urban settlements. Reprod Health. 2011, 8: 9-10.1186/1742-4755-8-9.

Meltzer-Brody S: New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. Dialogues Clin Neurosci. 2011, 13: 89-100.

Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ: A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010, 67: 1012-1024. 10.1001/archgenpsychiatry.2010.111.

Rahman A, Bunn J, Lovel H, Creed F: Association between antenatal depression and low birth weight in a developing country. Acta Psychiatr Scand. 2007, 115: 481-486. 10.1111/j.1600-0447.2006.00950.x.

Rahimi R, Nikfar S, Abdollahi M: Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006, 22: 571-575. 10.1016/j.reprotox.2006.03.019.

Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M: Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. J Clin Psychopharmacol. 2012, 32: 186-194. 10.1097/JCP.0b013e3182490eaf.

Malm H, Artama M, Gissler M, Ritvanen A: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011, 118: 111-120. 10.1097/AOG.0b013e318220edcc.

Colvin L, Slack-Smith L, Stanley FJ, Bower C: Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011, 91: 142-152. 10.1002/bdra.20773.

Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M: Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol. 2010, 2: 29-36.

Merlob P, Birk E, Sirota L, Linder N, Berant M, Stahl B, Klinger G: Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol. 2009, 85: 837-841. 10.1002/bdra.20615.

Wichman CL, Moore KM, Lang TR, St Sauver JL, Jr Heise RH, Watson WJ: Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009, 84: 23-27. 10.4065/84.1.23.

Einarson A, Koren G: Counseling pregnant women treated with paroxetine: concern about cardiac malformations. Can Fam Physician. 2006, 52: 593-594.

Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A: Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008, 66: 695-705.

Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J: Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev. 2008, 84: 689-697. 10.1016/j.earlhumdev.2008.06.008.

Einarson A, Pistelli A, De Santis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G: Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008, 165: 749-752. 10.1176/appi.ajp.2007.07060879.

Källén BA, Otterblad Olausson P: Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007, 79: 301-308. 10.1002/bdra.20327.

Wen SW, Walker M: The use of selective serotonin reuptake inhibitors in pregnancy. J Obstet Gynaecol Can. 2004, 26: 819-822.

Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sørensen HT: Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006, 17: 701-704. 10.1097/01.ede.0000239581.76793.ae.

Vial T, Cournot MP, Bernard N, Carlier P, Jonville-Bera P, Jean-Pastor MJ, Bajhoux C, Robert E, Elefant E, Descotes J: Paroxetine and congenital malformations: A prospective comparative study. Drug Saf. 2006, 29: 911-1010.

Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G: Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005, 193: 2004-2009. 10.1016/j.ajog.2005.05.012.

Malm H, Klaukka T, Neuvonen PJ: Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005, 106: 1289-1296. 10.1097/01.AOG.0000187302.61812.53.

Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE: Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003, 142 (4): 402-408. 10.1067/mpd.2003.139.

Costei AM, Kozer E, Ho T, Ito S, Koren G: Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002, 156: 1129-1132. 10.1001/archpedi.156.11.1129.

Diav-Citrin O, Shechtman S, Weinbaum D: Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. Teratology. 2002, 65: 298-

Simon GE, Cunningham ML, Davis RL: Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002, 159: 2055-2061. 10.1176/appi.ajp.159.12.2055.

Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001, 158: 1728-1730. 10.1176/appi.ajp.158.10.1728.

Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998, 279: 609-610. 10.1001/jama.279.8.609.

Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, Kulin N, Koren G: Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997, 336: 258-262. 10.1056/NEJM199701233360404.

Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996, 335: 1010-1015. 10.1056/NEJM199610033351402.

Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C: Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993, 269: 2246-2248. 10.1001/jama.1993.03500170076037.

Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH: Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009, 339: b3569-10.1136/bmj.b3569.

Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G: Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther. 2007, 29: 918-926. 10.1016/j.clinthera.2007.05.003.

Wurst KE, Poole C, Ephross SA, Olshan AF: First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010, 88: 159-170. 10.1002/bdra.20627.

Abdollahi M, Nikfar S, Hosseini-Tabatabaei A, Rezaie A: Interventions for preventing osteoporosis in women on heparin therapy during pregnancy. Cochrane Database Syst Rev. 2010, 6: CD008547-

Rahimi R, Nikfar S, Rezaie A, Abdollahi M: A meta-analysis on the efficacy and safety of combined vitamin C and E supplementation in preeclamptic women. Hypertens Pregnancy. 2009, 28 (4): 417-34. 10.3109/10641950802629667.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M: Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008, 25: 271-275. 10.1016/j.reprotox.2007.11.010.

Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G: Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci. 2002, 47 (7): 1526-1529. 10.1023/A:1015863018105.

Thông tin
Thông tin xuất bản

DARU Journal of Pharmaceutical Sciences

Thông tin tác giả